Generic drugs now make up more than 88% of all prescriptions filled in pharmacies in the United States and have provided nearly $1.7 trillion in health care savings in the past decade.1 Yet tensions still persist between brand-name drugs and generics. Fifty years ago, pharmaceutical companies hurled the word generic as an insult—a reference to often unauthorized copies made by small manufacturers with questionable assurances of product utility. Yet the growth of this new industry was already under way, spurred on by waves of patent expirations, Congressional inquiries, and increasing interests of purchasers in less expensive versions of essential medications.2(pp1-136)
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Sharfstein JM, Greene J. Promise and Peril for Generic Drugs. JAMA Intern Med. 2016;176(6):733–734. doi:10.1001/jamainternmed.2016.1720
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.